---
document_datetime: 2023-09-21 18:01:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/onsenal-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: onsenal-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 0.721516
conversion_datetime: 2025-12-19 00:02:23.792545
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 May 2004 please refer to module 8B.

| Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on authorised   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|-----------------------------------------------------|
| Update of sections 4.3 'Contraindications', 4.4 'Special warnings and special precautions for use', 4.5 'Pharmacodynamic Interactions', 4.8 'Undesirable effects', 5.1 'Pharmacodynamic properties' and 5.3 'Preclinical safety data' of the Summary of Product Characteristics (SPC) of the medicinal product Onsenal following the request from the CPMP following the adoption of the opinion on the referral procedure under article 31 of Directive 2001/83/EEC, for all medicinal products containing celecoxib, etoricoxib, parecoxib, rofecoxib and valdecoxib. The Package Leaflet (PL) has been updated accordingly. Modification of section 4.8 of the SPC by ranking ADRs for frequency within each system organ class, for alignment with celecoxib SPC as adopted through the referral procedure. A few sentences have been moved within the specific section, for alignment purposes. The Marketing Authorisation Holder (MAH) has taken this opportunity to correct a mistake in the section 4.2 of the French SPC for the 400mg capsule. On the basis of the information provided by the MAH and as set out in the appended variation assessment report, the CPMP considers this variation to be a Type II variation. | II-0001              | II                       | 26.02.04                            | 22.04.04                                            |

Scope Update  of  sections  4.3  'Contraindications',  4.4  'Special  warnings and special precautions for use', 4.5 'Pharmacodynamic Interactions',  4.8  'Undesirable  effects',  5.1  'Pharmacodynamic properties'  and  5.3  'Preclinical  safety  data'  of  the  Summary  of Product  Characteristics  (SPC)  of  the  medicinal  product  Onsenal following the request from the CPMP following the adoption of the opinion  on  the  referral  procedure  under  article 31  of  Directive 2001/83/EEC,  for all medicinal products containing celecoxib, etoricoxib, parecoxib, rofecoxib and valdecoxib. The Package Leaflet (PL) has been updated accordingly. Modification of section 4.8 of the SPC by ranking ADRs for frequency within each system organ  class,  for  alignment  with  celecoxib  SPC  as  adopted  through the referral procedure. A few sentences have been moved within the specific section, for alignment purposes. The Marketing Authorisation Holder (MAH) has taken this opportunity to correct a mistake in the section 4.2 of the French SPC for the 400mg capsule. On the basis of the information provided by the MAH and as set out in  the  appended  variation  assessment  report,  the  CPMP  considers this variation to be a Type II variation. 1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application. Medicinal product no longer authorised

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.